ZURICH (Reuters) - Novartis said its Sandoz division received approval from the European Commission for its biosimilar Zessly (infliximab) in... ...http://feeds.reuters.com/~r/reuters/INhealth/~3/RmN9KBxiNXU/novartis-receives-eu-approval-for-biosimilar-zessly-idINKCN1IP0P2
Requires you to share personal information like date of birth, income, location amongst other fields. This information alongwith your contact... ...http://www.business-standard.com/article/companies/biocon-monetisation-of-drug-pipeline-in-emerging-markets-to-boost-earnings-118041701457_1.html
CNBC-TV18’s Archana Shukla caught up with Nilesh Gupta on the sidelines of the pharma forum and asked him about the generic pharma market. ...http://www.moneycontrol.com/news/business/concern-is-that-established-players-like-sandoz-tevamoving-out-lupin_10568021.html
Novartis was created in 1996 through...